Sort
85,873 grants matching “alzheimers”
Imaging tau, amyloid, and neurodegeneration in PPA
$854,998Bradford C Dickerson · Massachusetts General Hospital · R01 · FY2019 · DC
Imaging tau, amyloid, and neurodegeneration in PPA
$854,998Bradford C Dickerson · Massachusetts General Hospital · R01 · FY2016 · DC
Noninvasive Low-cost Biomarkers for Preclinical Diagnosis and Longitudinal Tracking of Alzheimer's Disease Using Sleep and Resting State EEG
$854,981Patrick L. Purdon · Massachusetts General Hospital · R01 · FY2017 · AG
Data Management and Methods Core (DM&M)
$854,877Pedro L Gozalo · Brown University · P01 · FY2019 · AG
Atypical astrocytes in aging and Alzheimer's Disease
$854,851Chris G Dulla · Tufts University Boston · R01 · FY2024 · AG
A Novel Epigenetic Clock for Brain Aging
$854,832Francine Grodstein · Rush University Medical Center · R01 · FY2025 · AG
Role of age, dopamine, and tau related network disruption in setting a context for progression toward Alzheimer's Disease
$854,701Julius C Hedden · Massachusetts General Hospital · R01 · FY2017 · AG
Centralized assay datasets for modelling support of small drug discovery organizations
$854,677Sean Ekins · Collaborations Pharmaceuticals, Inc. · R44 · FY2022 · GM
NIH Director's Pioneer Award
$854,584Rosalind A Segal · Dana-Farber Cancer Inst · DP1 · FY2006 · OD
Regulation of y-secretase activity by modulatory proteins
$854,379Yueming Li · Sloan-Kettering Inst Can Research · R01 · FY2022 · AG
Omics Analyses of HIV and Substance Use Disorder
$854,351Vez Repunte-Canonigo · Scripps Research Institute, The · R01 · FY2022 · DA
Traumatic Brain Injury Anti-Seizure Prophylaxis in the Medicare Program
$854,181Lidia Maria Veras Rocha De Moura · Massachusetts General Hospital · R01 · FY2023 · AG
Systemic and dietary advanced glycation end products in type 2 diabetes-related cognitive decline and incident dementia: effects on Alzheimer's pathology and cerebrovascular disease
$854,145Michal Schnaider Beeri · Icahn School Of Medicine At Mount Sinai · R01 · FY2020 · AG
Validation and clinicaldevelopment of plasma EV protein biomarkers for minimally-invasive detection of Alzheimersdisease
$854,102Anton Iliuk · Tymora Analytical Operations, Llc · R44 · FY2025 · AG
Caregiving for Alzheimer's Disease and Related Dementias: Enhancing the National Study of Caregiving (NSOC)
$854,067Judith Kasper · Johns Hopkins University · R01 · FY2019 · AG
Deprescribing antipsychotics in patients with Alzheimers disease and related dementias and behavioral disturbance in skilled nursing facilities
$854,063Joshua K Lin · Brigham And Women'S Hospital · R01 · FY2024 · AG
A targeted analytical framework to optimize posthospitalization delirium pharmacotherapy in patients with Alzheimers disease and related dementias
$854,063Joshua K Lin · Brigham And Women'S Hospital · R01 · FY2024 · AG
Modifiable cardiovascular factors linking type 2 diabetes and Alzheimer's disease
$854,023Antonio Convit · New York University School Of Medicine · R01 · FY2018 · AG
Rates and mechanisms of age-related somatic mutation in normal and Alzheimer brain
$853,949Christopher A Walsh · Boston Children'S Hospital · R01 · FY2023 · AG
Fluorescent IRE Sensor for Synucleinopathy Drug Discovery
$853,817Wen Shen · Lucerna, Inc. · R44 · FY2022 · NS
Design And Development Of Experimental Therapeutics
$853,810Nigel H. Greig · National Institute On Aging · ZIA · FY2020 · AG
Neuropathology Core
$853,684Richard Justin Perrin · Northern California Institute/Res/Edu · U19 · FY2022 · AG
ApoE Genotype-Directed Drug Repositioning and Combination Therapy for Alzheimer's Disease
$853,475Yadong Huang · J. David Gladstone Institutes · R01 · FY2021 · AG
ApoE Genotype-Directed Drug Repositioning and Combination Therapy for Alzheimer's Disease
$853,475Yadong Huang · J. David Gladstone Institutes · R01 · FY2020 · AG
ApoE Genotype-Directed Drug Repositioning and Combination Therapy for Alzheimer's Disease
$853,475Yadong Huang · J. David Gladstone Institutes · R01 · FY2019 · AG